Miami Cancer Institute - Multispecialty Grand Rounds Evaluation - March 9, 2026

Please select one: *

I am in active clinical practice

I am retired

I am a student

Other

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable

	5	4	3	2	1	NA
The skills learned in this CME course enhanced my professional competence.	The skills learned in this CME course enhanced my professional competence. - 5	The skills learned in this CME course enhanced my professional competence. - 4	The skills learned in this CME course enhanced my professional competence. - 3	The skills learned in this CME course enhanced my professional competence. - 2	The skills learned in this CME course enhanced my professional competence. - 1	The skills learned in this CME course enhanced my professional competence. - NA
The skills learned in this CME course will be applied in the treatment of my patients	The skills learned in this CME course will be applied in the treatment of my patients - 5	The skills learned in this CME course will be applied in the treatment of my patients - 4	The skills learned in this CME course will be applied in the treatment of my patients - 3	The skills learned in this CME course will be applied in the treatment of my patients - 2	The skills learned in this CME course will be applied in the treatment of my patients - 1	The skills learned in this CME course will be applied in the treatment of my patients - NA

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied

	5	4	3	2	1
Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes.	Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes. - 5	Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes. - 4	Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes. - 3	Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes. - 2	Explain the biological and clinical foundations of immune checkpoint inhibition across the major gastroesophageal cancer subtypes. - 1
Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability.	Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability. - 5	Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability. - 4	Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability. - 3	Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability. - 2	Evaluate and interpret predictive biomarkers—including PD-L1 CPS, MSI-H, and HER2—while recognizing their practical limitations and variability. - 1
Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers.	Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers. - 5	Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers. - 4	Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers. - 3	Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers. - 2	Integrate evidence-based immunotherapy approaches into treatment planning for localized, metastatic, and refractory gastroesophageal cancers. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice

	5	4	3	2	1
Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings.	Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings. - 5	Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings. - 4	Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings. - 3	Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings. - 2	Apply evidence-based immunotherapy strategies across localized, metastatic and refractory settings. - 1
Interpret key predictive biomarkers and their limitations?	Interpret key predictive biomarkers and their limitations? - 5	Interpret key predictive biomarkers and their limitations? - 4	Interpret key predictive biomarkers and their limitations? - 3	Interpret key predictive biomarkers and their limitations? - 2	Interpret key predictive biomarkers and their limitations? - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

If you do not plan to implement any new skills/strategies in your clinical practice, what is keeping you from doing so?

Please provide any additional comments or suggestions.

Name and ABS ID Required to claim MOC *

You are here

Miami Cancer Institute - Multispecialty Grand Rounds Evaluation - March 9, 2026